2. Academic Validation
  3. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles

Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles

  • Bioorg Med Chem Lett. 2005 Aug 1;15(15):3496-500. doi: 10.1016/j.bmcl.2005.05.129.
John F Miller 1,  Michael Brieger,  Eric S Furfine,  Richard J Hazen,  Istvan Kaldor,  David Reynolds,  Ronald G Sherrill,  Andrew Spaltenstein
Affiliations

Affiliation

  • 1 GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA. john.6.miller@gsk.com
PMID: 15990305 DOI: 10.1016/j.bmcl.2005.05.129
Abstract

A novel series of tyrosine-derived HIV Protease Inhibitors was synthesized and evaluated for in vitro Antiviral activity against wild-type virus and two protease inhibitor-resistant viruses. All of the compounds had wild-type Antiviral activities that were similar to or greater than several currently marketed HIV Protease Inhibitors. In addition, a number of compounds in this series were more potent against the drug-resistant mutant viruses than they were against wild-type virus.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z